Menu Search
Equities

Aarti Drugs Ltd

AARTIDRUGS:NSI

Aarti Drugs Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)490.00
  • Today's Change-5.95 / -1.20%
  • Shares traded81.62k
  • 1 Year change+2.30%
  • Beta1.0488
Data delayed at least 15 minutes, as of Nov 08 2024 10:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Aarti Drugs Ltd had revenues fall -6.90% from 27.16bn to 25.29bn, though the company grew net income 3.07% from 1.66bn to 1.71bn.
Gross margin34.60%
Net profit margin6.40%
Operating margin9.86%
Return on assets6.37%
Return on equity12.24%
Return on investment9.62%
More ▼

Cash flow in INRView more

In 2024, cash reserves at Aarti Drugs Ltd fell by 7.61m. However, the company earned 3.59bn from its operations for a Cash Flow Margin of 14.19%. In addition the company used 2.24bn on investing activities and also paid 1.36bn in financing cash flows.
Cash flow per share22.44
Price/Cash flow per share21.75
Book value per share139.96
Tangible book value per share139.71
More ▼

Balance sheet in INRView more

Aarti Drugs Ltd has a Debt to Total Capital ratio of 31.59%, a higher figure than the previous year's 17.58%.
Current ratio1.61
Quick ratio1.01
Total debt/total equity0.462
Total debt/total capital0.3159
More ▼

Growth rates in INR

Year on year, growth in earnings per share excluding extraordinary items increased 3.82%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
EPS growth(5 years)14.40
EPS (TTM) vs
TTM 1 year ago		-14.73
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.